Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.7
4.6
Journals
Pharmaceuticals
Special Issues
The Medical Applications of Novel PET Radiopharmaceuticals
share announcement

The Medical Applications of Novel PET Radiopharmaceuticals

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Radiopharmaceutical Sciences".

Deadline for manuscript submissions: 25 May 2024 | Viewed by 1499

Special Issue Editors

Dr. Jonathan Vigne

E-Mail Website
Guest Editor
1. Department of Nuclear Medicine, CHU de Caen Normandie, Normandie Université, UNICAEN, 14000 Caen, France
2. PhIND, Centre Cyceron, Institut Blood and Brain @ Caen-Normandie, INSERM U1237, 14000 Caen, France
Interests: nuclear medicine; radiopharmaceuticals; molecular imaging; radiopharmacy; theranostics
Dr. Florent L. Besson

E-Mail Website
Guest Editor
School of Medicine, Université Paris-Saclay, 94270 Le Kremlin-Bicêtre, France
Interests: nuclear medicine; PET imaging

Special Issue Information

Dear Colleagues,

This medical field is constantly seeking innovative solutions to improve diagnostic and treatment using tailored approaches. One such advancement lies in the utilization of novel positron emission tomography (PET) radiotracers. These cutting-edge radiotracers have shown immense potential in revolutionizing medical applications. With the rapid development of medical imaging technologies, PET has emerged as a powerful tool for visualizing and quantifying physiological processes within the human body. Traditional PET radiotracers have been widely used to diagnose and monitor various conditions, including cancer, cardiovascular diseases, and neurological disorders. However, the introduction of novel PET radiotracers has taken medical imaging to new heights.These innovative radiotracers are designed to target specific molecular and cellular processes, allowing for more accurate and precise imaging. By leveraging the unique properties of these radiotracers, medical professionals can gain valuable insight in the molecular mechanisms underlying these diseases. This knowledge facilitates early detection, personalized treatment planning, and therapeutic monitoring.The medical applications of novel PET radiotracers span across multiple disciplines. In oncology, these radiotracers enable the identification of specific tumor markers, aiding in tumor characterization, staging, and treatment response assessment. In cardiology, they can assess myocardial perfusion, monitor metabolism, and identify atherosclerotic plaques. Furthermore, in neurology, novel PET radiotracers facilitate the visualization of neuroreceptors, neurotransmitters, and amyloid plaques, assisting in the diagnosis and management of neurodegenerative disorders.This Special Issue aims to explore the significance and impact of novel PET radiotracers toward various medical applications. It is open to original research and review articles. We look forward to receiving your contributions.

Dr. Jonathan Vigne
Dr. Florent L. Besson
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • nuclear medicine
  • radiotracers
  • radiopharmaceuticals
  • positron emission tomography
  • diagnostics
  • medical applications

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

20 pages, 3480 KiB  
Review
Diagnostic Accuracy of [68Ga]Ga Labeled Fibroblast-Activation Protein Inhibitors in Detecting Head and Neck Cancer Lesions Using Positron Emission Tomography: A Systematic Review and a Meta-Analysis
by Alessio Rizzo, Alberto Miceli, Manuela Racca, Matteo Bauckneht, Silvia Morbelli, Domenico Albano, Francesco Dondi, Francesco Bertagna, Danilo Galizia, Barbara Muoio, Salvatore Annunziata and Giorgio Treglia
Pharmaceuticals 2023, 16(12), 1664; https://doi.org/10.3390/ph16121664 - 30 Nov 2023
Cited by 2 | Viewed by 1207
Abstract
Several studies have examined the use of positron emission tomography (PET) using [68Ga]Ga-radiolabeled fibroblast-activation protein inhibitors (FAPi) across multiple subtypes of head and neck cancer (HNC). The purpose of the present study was to evaluate the diagnostic accuracy of a newly [...] Read more.
Several studies have examined the use of positron emission tomography (PET) using [68Ga]Ga-radiolabeled fibroblast-activation protein inhibitors (FAPi) across multiple subtypes of head and neck cancer (HNC). The purpose of the present study was to evaluate the diagnostic accuracy of a newly developed molecular imaging approach in the context of HNC through a comprehensive review and meta-analysis. A thorough literature review was conducted to identify scholarly articles about the diagnostic effectiveness of FAP-targeted PET imaging. The present study incorporates original publications assessing the efficacy of this innovative molecular imaging test in both newly diagnosed and previously treated HNC patients. This systematic review examined eleven investigations, of which nine were deemed suitable for inclusion in the subsequent meta-analysis. The quantitative synthesis yielded a pooled detection rate of 99% for primary HNC lesions. Additionally, on a per patient-based analysis, the pooled sensitivity and specificity for regional lymph node metastases were found to be 90% and 84%, respectively. The analysis revealed a statistical heterogeneity among the studies for the detection rate of primary HNC lesions. The quantitative findings presented in this study indicate a favorable diagnostic performance of FAP-targeted PET imaging in detecting primary HNC tumors. In contrast, discordant results concerning the diagnostic accuracy of lymph node metastases were found. However, further multicentric trials are required to validate the efficacy of FAP-targeted PET in this specific group of patients. Full article
(This article belongs to the Special Issue The Medical Applications of Novel PET Radiopharmaceuticals)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop